Kuros statement on media inquiry concerning former Board memberAd-hoc announcement pursuant to Article 53 of the SIX listing rules
Kuros Biosciences announces changes in the Board of DirectorsAd-hoc announcement pursuant to Article 53 of the SIX listing rules
Kuros Biosciences Reports First Half of 2025 ResultsAd-hoc announcement pursuant to Article 53 of the SIX listing rules
Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance
Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Market Day in Zürich Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Markets Day in Zürich
Annual General Meeting of Kuros Biosciences approves all resolutionsAnnual General Meeting of Kuros Biosciences approves all resolutions
Kuros Biosciences grows sales to CHF 75.6 million for 2024Ad-hoc announcement pursuant to Article 53 of the SIX listing rules
